Search results

Dans cette étude les auteurs ont mis en relation trois appréciations différentes de la concentration d'enfants : dans un premier temps les enfants ont subi un test de concentration et ils ont été évalués par leur enseignant de classe préscolaire. Un an plus tard, les mêmes enfants furent évalués par leur maître de première année primaire. Conjointement à la concentration furent appréciés les éléments reliés à celle-ci : la motivation et l'intelligence (mesurée également par un test) ainsi que la présence ou l'absence de difficultés de comportement.
Les jugements portant sur la concentration étaient corrèlès aux résultats du test y afférant, mais avaient des relations plus étroites avec les jugements formulés par les enseignants sur les autres aspects des enfants.
Des 254 enfants suivis pendant les deux années 26 % ont été jugés de façon différente en dernière année préscolaire qu'en première année primaire, alors que 63 % étaient jugés toujours comme concentrés et II % toujours comme non concentrés. Ce dernier groupe d'enfants recueille en outre toutes les qualifications négatives possibles : troubles de comportement, non motivés et non intelligents et cela bien qu'un test d'intelligence non verbale n'ait pas montré de différence avec les autres groupes d'enfants.

International audience ; Background: Chronic urticaria (CU) is a common disease, characterized by the recurrent appearance of wheals, angioedema or both for more than 6 weeks. Its underlying biology is not well understood, and many patients do not obtain sufficient relief from recommended treatments. Patient registries are rapidly growing as a form of research, because they can provide powerful, data-driven insights about the epidemiology of diseases, real-world effectiveness of treatments, rare patient types, safety monitoring, healthcare costs and opportunities for quality improvement of healthcare delivery.Objectives: The Chronic Urticaria Registry (CURE) has been designed to improve the scientific understanding, clinical treatment and healthcare planning of CU patients. This report describes the rationale, methods and initial implementation of this registry.Methods: Chronic Urticaria Registry is an ongoing, prospective, international, multicentre, observational, voluntary registry of patients with CU. Participation in CURE is open to any physician treating CU patients, regardless of location, medical specialty or type of practice setting. CURE aims to collect data on all CU patients, with no intentional selection or exclusion criteria. It collects baseline and follow-up data on the patient's demographics, history, symptoms, trigger and risk factors, therapies and healthcare utilization.Results: Chronic Urticaria Registry is a landmark achievement of the global urticaria medical community. As of 26 February 2020, 39 centres around the world have joined the registry and 35 have entered baseline data on a total of 2946 patients. Publications of this data will be forthcoming soon.Conclusions: Chronic Urticaria Registry is eagerly seeking the participation of more physicians and the support of more governmental, charitable and commercial sponsors from around the world. Here, in this paper, we invite other physicians to join this unique project to improve the lives of patients with CU.

International audience ; Background: Chronic urticaria (CU) is a common disease, characterized by the recurrent appearance of wheals, angioedema or both for more than 6 weeks. Its underlying biology is not well understood, and many patients do not obtain sufficient relief from recommended treatments. Patient registries are rapidly growing as a form of research, because they can provide powerful, data-driven insights about the epidemiology of diseases, real-world effectiveness of treatments, rare patient types, safety monitoring, healthcare costs and opportunities for quality improvement of healthcare delivery.Objectives: The Chronic Urticaria Registry (CURE) has been designed to improve the scientific understanding, clinical treatment and healthcare planning of CU patients. This report describes the rationale, methods and initial implementation of this registry.Methods: Chronic Urticaria Registry is an ongoing, prospective, international, multicentre, observational, voluntary registry of patients with CU. Participation in CURE is open to any physician treating CU patients, regardless of location, medical specialty or type of practice setting. CURE aims to collect data on all CU patients, with no intentional selection or exclusion criteria. It collects baseline and follow-up data on the patient's demographics, history, symptoms, trigger and risk factors, therapies and healthcare utilization.Results: Chronic Urticaria Registry is a landmark achievement of the global urticaria medical community. As of 26 February 2020, 39 centres around the world have joined the registry and 35 have entered baseline data on a total of 2946 patients. Publications of this data will be forthcoming soon.Conclusions: Chronic Urticaria Registry is eagerly seeking the participation of more physicians and the support of more governmental, charitable and commercial sponsors from around the world. Here, in this paper, we invite other physicians to join this unique project to improve the lives of patients with CU.

International audience ; Background: Chronic urticaria (CU) is a common disease, characterized by the recurrent appearance of wheals, angioedema or both for more than 6 weeks. Its underlying biology is not well understood, and many patients do not obtain sufficient relief from recommended treatments. Patient registries are rapidly growing as a form of research, because they can provide powerful, data-driven insights about the epidemiology of diseases, real-world effectiveness of treatments, rare patient types, safety monitoring, healthcare costs and opportunities for quality improvement of healthcare delivery.Objectives: The Chronic Urticaria Registry (CURE) has been designed to improve the scientific understanding, clinical treatment and healthcare planning of CU patients. This report describes the rationale, methods and initial implementation of this registry.Methods: Chronic Urticaria Registry is an ongoing, prospective, international, multicentre, observational, voluntary registry of patients with CU. Participation in CURE is open to any physician treating CU patients, regardless of location, medical specialty or type of practice setting. CURE aims to collect data on all CU patients, with no intentional selection or exclusion criteria. It collects baseline and follow-up data on the patient's demographics, history, symptoms, trigger and risk factors, therapies and healthcare utilization.Results: Chronic Urticaria Registry is a landmark achievement of the global urticaria medical community. As of 26 February 2020, 39 centres around the world have joined the registry and 35 have entered baseline data on a total of 2946 patients. Publications of this data will be forthcoming soon.Conclusions: Chronic Urticaria Registry is eagerly seeking the participation of more physicians and the support of more governmental, charitable and commercial sponsors from around the world. Here, in this paper, we invite other physicians to join this unique project to improve the lives of patients with CU.

International audience ; Background: Chronic urticaria (CU) is a common disease, characterized by the recurrent appearance of wheals, angioedema or both for more than 6 weeks. Its underlying biology is not well understood, and many patients do not obtain sufficient relief from recommended treatments. Patient registries are rapidly growing as a form of research, because they can provide powerful, data-driven insights about the epidemiology of diseases, real-world effectiveness of treatments, rare patient types, safety monitoring, healthcare costs and opportunities for quality improvement of healthcare delivery.Objectives: The Chronic Urticaria Registry (CURE) has been designed to improve the scientific understanding, clinical treatment and healthcare planning of CU patients. This report describes the rationale, methods and initial implementation of this registry.Methods: Chronic Urticaria Registry is an ongoing, prospective, international, multicentre, observational, voluntary registry of patients with CU. Participation in CURE is open to any physician treating CU patients, regardless of location, medical specialty or type of practice setting. CURE aims to collect data on all CU patients, with no intentional selection or exclusion criteria. It collects baseline and follow-up data on the patient's demographics, history, symptoms, trigger and risk factors, therapies and healthcare utilization.Results: Chronic Urticaria Registry is a landmark achievement of the global urticaria medical community. As of 26 February 2020, 39 centres around the world have joined the registry and 35 have entered baseline data on a total of 2946 patients. Publications of this data will be forthcoming soon.Conclusions: Chronic Urticaria Registry is eagerly seeking the participation of more physicians and the support of more governmental, charitable and commercial sponsors from around the world. Here, in this paper, we invite other physicians to join this unique project to improve the lives of patients with CU.

Urticaria is a frequent disease. The lifetime prevalence for urticaria is approximately 20%. Urticaria not only causes a decrease in quality of life, but also affects performance at work and school and, as such, is a member of the group of severe allergic diseases. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors, and pathomechanisms. In addition, it outlines evidence-based approaches to economical diagnosis for different subtypes of urticaria. The correct management of urticaria, which is of paramount importance for patients, is very complex and is consequently covered in a separate guideline. This German language guideline was prepared on the basis of the international English language guideline, which was acknowledged by UEMS (European Union of Medical Specialists), taking into account medical conditions in the German language area. This guideline, together with its sister guideline on the management of urticaria, is the result of a consensus reached during a panel discussion at the 3rd International Consensus Meeting on Urticaria, "Urticaria 2008", a joint initiative of the Dermatology Section of the EAACI (European Academy of Allergy and Clinical Immunology), the EU-funded network of excellence GA(2)LEN (Global Allergy and Asthma European Network), the EDF (European Dermatology Forum) and the WAO (World Allergy Organization). For the first time, given that evidence was sufficient, the Grading-of-Recommendations-Assessment- De vel opment-and- Evaluation-(GRADE)-Method was used here as far as possible.

Urticaria is a frequent disease. The lifetime prevalence for urticaria is approximately 20%. Urticaria not only causes a decrease in quality of life, but also affects performance at work and school and, as such, is a member of the group of severe allergic diseases. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors, and pathomechanisms. In addition, it outlines evidence-based approaches to economical diagnosis for different subtypes of urticaria. The correct management of urticaria, which is of paramount importance for patients, is very complex and is consequently covered in a separate guideline. This German language guideline was prepared on the basis of the international English language guideline, which was acknowledged by UEMS (European Union of Medical Specialists), taking into account medical conditions in the German language area. This guideline, together with its sister guideline on the management of urticaria, is the result of a consensus reached during a panel discussion at the 3rd International Consensus Meeting on Urticaria, Urticaria 2008, a joint initiative of the Dermatology Section of the EAACI (European Academy of Allergy and Clinical Immunology), the EU-funded network of excellence GA(2)LEN (Global Allergy and Asthma European Network), the EDF (European Dermatology Forum) and the WAO (World Allergy Organization). For the first time, given that evidence was sufficient, the Grading-of-Recommendations-Assessment- De vel opment-and- Evaluation-(GRADE)-Method was used here as far as possible.

This guideline is the result of a systematic literature review using the 'Grading of Recommendations Assessment, Development and Evaluation' (GRADE) methodology and a structured consensus conference held on 28 and 29 November 2012, in Berlin. It is a joint initiative of the Dermatology Section of the European Academy of Allergy and Clinical Immunology (EAACI), the EU-funded network of excellence, the Global Allergy and Asthma European Network (GA(2)LEN), the European Dermatology Forum (EDF), and the World Allergy Organization (WAO) with the participation of delegates of 21 national and international societies. Urticaria is a frequent, mast cell-driven disease, presenting with wheals, angioedema, or both. the life-time prevalence for acute urticaria is approximately 20%. Chronic spontaneous urticaria and other chronic forms of urticaria do not only cause a decrease in quality of life, but also affect performance at work and school and, as such, are members of the group of severe allergic diseases. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms. in addition, it outlines evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). ; Charite, Allergy Ctr Charite, Dept Dermatol & Allergy, D-10117 Berlin, Germany ; Med Univ Graz, Dept Dermatol, Graz, Austria ; Clin San Carlo, Allergy Clin, Paderno Dugnano, MI, Italy ; Univ Southern Denmark, Odense Univ Hosp, Dept Dermatol & Allergy Ctr, Odense, Denmark ; Med Univ Silesia, Allergol & Clin Immunol Katowice, Dept Internal Dis, Zabrze, Poland ; Univ Genoa, IRCCS AOU SanMartino, Genoa, Italy ; Universidade Federal de São Paulo, Dept Clin Immunol & Allergy, São Paulo, Brazil ; Univ Autonoma Barcelona, Hosp Mar Parc Salut Mar, E-08193 Barcelona, Spain ; Dr DY Patil Med Coll & Hosp, Dept Dermatol, Navi Mumbai, India ; Fac Med, Dermatol Clin, Coimbra, Portugal ; Univ Hosp, Coimbra, Portugal ; Guys & St Thomas Hosp NHS Fdn Trust, St Johns Inst Dermatol, London, England ; Ctr Appl Res Allergy Quebec, Quebec City, PQ, Canada ; Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Dermatol, Hiroshima, Japan ; Med Univ S Carolina, Dept Med, Div Pulm & Crit Care Med, Charleston, SC USA ; Hannover Med Sch, Dept Dermatol & Allergy, Hannover, Germany ; Pantai Hosp Kuala Lumpur, Dept Paediat, Kuala Lumpur, Malaysia ; Univ Hosp Tenon, Dept Dermatol & Allergy, Paris, France ; Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA ; Ctr Medicodocente Trinidad, Allergy & Clin Immunol Dept, Caracas, Venezuela ; Univ Hosp, Dept Dermatol, Allergy Unit, Zurich, Switzerland ; Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada ; Univ Manitoba, Dept Immunol, Winnipeg, MB, Canada ; Univ Med Ctr Mainz, Dept Dermatol, Mainz, Germany ; Univ Toronto, Div Allergy & Clin Immunol, Toronto, ON, Canada ; Technion, Fac Med, Bnai Zion Med Ctr, Haifa, Israel ; Univ Bari, Dept Biomed Sci & Human Oncol, Unit Dermatol & Venereol, Bari, Italy ; Peking Univ, Hosp 1, Dept Dermatol, Beijing 100871, Peoples R China ; Universidade Federal de São Paulo, Dept Clin Immunol & Allergy, São Paulo, Brazil ; Web of Science